ThromboGenics NV Business Update
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013.
LEUVEN, Belgium, May 16, 2013 /PRNewswire/ - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013.
During 2013, ThromboGenics delivered a number of key corporate milestones, the most important of which was the launch of JETREA® (ocriplasmin) in the US on 14 January via its own commercial organization. ThromboGenics' partner outside the US, Alcon, launched JETREA® in the UK and Germany after its approval by the European Commission in March 2013. The EU approval and the launch of JETREA® in the UK led to ThromboGenics receiving two equal milestones from Alcon amounting to a total of €90 million.
Help employers find you! Check out all the jobs and post your resume.